• Matteo Morotti, Hooman Soleymani Majd, Jvan Casarin, Moiad Alazzam, and Stephen Damato.
• Department of Gynecological Oncology, Oxford University Hospital NHS Foundation Trust, Oxford, UK - drmorottimatteo@gmail.com.
• Minerva Med. 2021 Feb 1; 112 (1): 20-30.

AbstractHigh-grade endometrial cancers (ECs) are an aggressive subset of ECs accounting for 70-80% of EC-related deaths. Currently, staging surgery, together with chemotherapy or radiotherapy, is the primary treatment strategy for these cancers. The widespread use of next-generation sequencing has led to a refined understanding of EC's genomics with important information for diagnosis and therapy for individual patients (precision medicine). However, advances in the genomics assessment of high-grade tumors have been slower due to their lower incidence than low-grade EC. This article will briefly introduce the current state of knowledge of the genomics of G3 endometrioid EC, serous uterine cancer, clear cell uterine carcinoma and uterine carcinosarcoma and discuss its implications for diagnosis and targeted therapy.

11 keywords...

hide…